-
1
-
-
33750606061
-
Long-term follow-up of patients with NAFLD and elevated liver enzymes
-
Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.
-
(2006)
Hepatology
, vol.44
, pp. 865-873
-
-
Ekstedt, M.1
Franzen, L.E.2
Mathiesen, U.L.3
-
2
-
-
79959573040
-
Endpoints and clinical trial design for nonalcoholic steatohepatitis
-
Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344-53.
-
(2011)
Hepatology
, vol.54
, pp. 344-353
-
-
Sanyal, A.J.1
Brunt, E.M.2
Kleiner, D.E.3
-
4
-
-
84861543083
-
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
-
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005-23.
-
(2012)
Hepatology
, vol.55
, pp. 2005-2023
-
-
Chalasani, N.1
Younossi, Z.2
Lavine, J.E.3
-
5
-
-
84877900838
-
Gastrointestinal complications of obesity: Non-alcoholic fatty liver disease (NAFLD) and its sequelae
-
Karlas T, Wiegand J, Berg T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab 2013;27:195-208.
-
(2013)
Best Pract Res Clin Endocrinol Metab
, vol.27
, pp. 195-208
-
-
Karlas, T.1
Wiegand, J.2
Berg, T.3
-
6
-
-
84863989690
-
Review article: Non-alcoholic fatty liver disease and osteoporosis: Clinical and molecular crosstalk
-
Yilmaz Y. Review article: non-alcoholic fatty liver disease and osteoporosis: clinical and molecular crosstalk. Aliment Pharmacol Ther 2012;36:345-52.
-
(2012)
Aliment Pharmacol Ther
, vol.36
, pp. 345-352
-
-
Yilmaz, Y.1
-
7
-
-
77955507529
-
Non-alcoholic fatty liver disease: The hepatic consequence of obesity and the metabolic syndrome
-
Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010;69: 211-20.
-
(2010)
Proc Nutr Soc
, vol.69
, pp. 211-220
-
-
Moore, J.B.1
-
9
-
-
77952529040
-
A position statement on NAFLD/NASH based on the EASL 2009 special conference
-
Ratziu V, Bellentani S, Cortez-Pinto H, Day C,Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53:372-84.
-
(2010)
J Hepatol
, vol.53
, pp. 372-384
-
-
Ratziu, V.1
Bellentani, S.2
Cortez-Pinto, H.3
Day Cmarchesini, G.4
-
10
-
-
12144259379
-
Magnetic resonance spectroscopy to measure hepatic triglyceride content: Prevalence of hepatic steatosis in the general population
-
Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005;288:E462-8.
-
(2005)
Am J Physiol Endocrinol Metab
, vol.288
, pp. E462-E468
-
-
Szczepaniak, L.S.1
Nurenberg, P.2
Leonard, D.3
-
11
-
-
10644220306
-
Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
-
Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-95.
-
(2004)
Hepatology
, vol.40
, pp. 1387-1395
-
-
Browning, J.D.1
Szczepaniak, L.S.2
Dobbins, R.3
-
12
-
-
80053581540
-
Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States
-
Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249-53.
-
(2011)
Gastroenterology
, vol.141
, pp. 1249-1253
-
-
Charlton, M.R.1
Burns, J.M.2
Pedersen, R.A.3
Watt, K.D.4
Heimbach, J.K.5
Dierkhising, R.A.6
-
13
-
-
34250332701
-
What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific?
-
Fan JG, Saibara T, Chitturi S, et al. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol 2007;22:794-800.
-
(2007)
J Gastroenterol Hepatol
, vol.22
, pp. 794-800
-
-
Fan, J.G.1
Saibara, T.2
Chitturi, S.3
-
14
-
-
19944394555
-
Second World Congress on the Insulin Resistance Syndrome: Insulin resistance syndrome and nonalcoholic fatty liver disease
-
Bloomgarden ZT. Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care 2005;28:1518-23.
-
(2005)
Diabetes Care
, vol.28
, pp. 1518-1523
-
-
Bloomgarden, Z.T.1
-
15
-
-
0034831067
-
Nonalcoholic steatohepatitis
-
Reid AE. Nonalcoholic steatohepatitis. Gastroenterology 2001;121: 710-23.
-
(2001)
Gastroenterology
, vol.121
, pp. 710-723
-
-
Reid, A.E.1
-
16
-
-
84865545850
-
Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis
-
Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 2012;56:943-51.
-
(2012)
Hepatology
, vol.56
, pp. 943-951
-
-
Loomba, R.1
Abraham, M.2
Unalp, A.3
-
17
-
-
0037382786
-
Nonalcoholic fatty liver, steatohepatitis,and themetabolic syndrome
-
Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis,and themetabolic syndrome.Hepatology2003;37:917-23.
-
(2003)
Hepatology
, vol.37
, pp. 917-923
-
-
Marchesini, G.1
Bugianesi, E.2
Forlani, G.3
-
18
-
-
53549112749
-
Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: Causal effect or epiphenomenon?
-
Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia 2008;51:1947-53.
-
(2008)
Diabetologia
, vol.51
, pp. 1947-1953
-
-
Targher, G.1
Marra, F.2
Marchesini, G.3
-
19
-
-
0037129380
-
Nonalcoholic fatty liver disease
-
Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346: 1221-31.
-
(2002)
N Engl J Med
, vol.346
, pp. 1221-1231
-
-
Angulo, P.1
-
20
-
-
0141532275
-
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone
-
Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17.
-
(2003)
Hepatology
, vol.38
, pp. 1008-1017
-
-
Neuschwander-Tetri, B.A.1
Brunt, E.M.2
Wehmeier, K.R.3
Oliver, D.4
Bacon, B.R.5
-
21
-
-
1442355447
-
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
-
Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39: 188-96.
-
(2004)
Hepatology
, vol.39
, pp. 188-196
-
-
Promrat, K.1
Lutchman, G.2
Uwaifo, G.I.3
-
23
-
-
33751545838
-
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
-
Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl JMed 2006;355:2297-307.
-
(2006)
N Engl JMed
, vol.355
, pp. 2297-2307
-
-
Belfort, R.1
Harrison, S.A.2
Brown, K.3
-
24
-
-
45549091794
-
Clinical trial: Insulinsensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis
-
Idilman R, Mizrak D, Corapcioglu D, et al. Clinical trial: insulinsensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2008;28:200-8.
-
(2008)
Aliment Pharmacol Ther
, vol.28
, pp. 200-208
-
-
Idilman, R.1
Mizrak, D.2
Corapcioglu, D.3
-
25
-
-
80055042241
-
The role of thiazolidinediones in non-alcoholic steatohepatitis: A systematic review and meta analysis
-
Mahady SE, Webster AC, Walker S, Sanyal A, George J. The role of thiazolidinediones in non-alcoholic steatohepatitis: a systematic review and meta analysis. J Hepatol 2011;55:1383-90.
-
(2011)
J Hepatol
, vol.55
, pp. 1383-1390
-
-
Mahady, S.E.1
Webster, A.C.2
Walker, S.3
Sanyal, A.4
George, J.5
-
27
-
-
68549101842
-
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration
-
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009;339: b2700.
-
(2009)
BMJ
, vol.339
, pp. b2700
-
-
Liberati, A.1
Altman, D.G.2
Tetzlaff, J.3
-
28
-
-
77951874018
-
Pioglitazone, Vitamin E, or placebo for nonalcoholic steatohepatitis
-
Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362: 1675-85.
-
(2010)
N Engl J Med
, vol.362
, pp. 1675-1685
-
-
Sanyal, A.J.1
Chalasani, N.2
Kowdley, K.V.3
-
29
-
-
46349088361
-
Rosiglitazone for nonalcoholic steatohepatitis: One-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial
-
Ratziu V, Giral P, Jacqueminet S, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 2008;135:100-10.
-
(2008)
Gastroenterology
, vol.135
, pp. 100-110
-
-
Ratziu, V.1
Giral, P.2
Jacqueminet, S.3
-
30
-
-
53049101877
-
Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
-
Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-84.
-
(2008)
Gastroenterology
, vol.135
, pp. 1176-1184
-
-
Aithal, G.P.1
Thomas, J.A.2
Kaye, P.V.3
-
31
-
-
34548306770
-
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis
-
Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007;46:424-9.
-
(2007)
Hepatology
, vol.46
, pp. 424-429
-
-
Lutchman, G.1
Modi, A.2
Kleiner, D.E.3
-
33
-
-
83555164835
-
Meta-analysis: Pioglitazone improves liver histology and fibrosis in patients with nonalcoholic steatohepatitis
-
Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2012;35:66-75.
-
(2012)
Aliment Pharmacol Ther
, vol.35
, pp. 66-75
-
-
Boettcher, E.1
Csako, G.2
Pucino, F.3
Wesley, R.4
Loomba, R.5
-
34
-
-
84945185644
-
Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis
-
Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology 2015;62:1417-32.
-
(2015)
Hepatology
, vol.62
, pp. 1417-1432
-
-
Singh, S.1
Khera, R.2
Allen, A.M.3
Murad, M.H.4
Loomba, R.5
-
35
-
-
79960109765
-
Pathophysiology of non-alcoholic steatohepatitis and basis for treatment
-
Pinzani M. Pathophysiology of non-alcoholic steatohepatitis and basis for treatment. Dig Dis 2011;29:243-8.
-
(2011)
Dig Dis
, vol.29
, pp. 243-248
-
-
Pinzani, M.1
-
36
-
-
77952580372
-
Metabolic factors and nonalcoholic fatty liver disease as co-factors in other liver diseases
-
Powell EE, Jonsson JR, Clouston AD. Metabolic factors and nonalcoholic fatty liver disease as co-factors in other liver diseases. Dig Dis 2010;28:186-91.
-
(2010)
Dig Dis
, vol.28
, pp. 186-191
-
-
Powell, E.E.1
Jonsson, J.R.2
Clouston, A.D.3
-
37
-
-
30944455145
-
Insulin resistance: A metabolic pathway to chronic liver disease
-
Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42: 987-1000.
-
(2005)
Hepatology
, vol.42
, pp. 987-1000
-
-
Bugianesi, E.1
McCullough, A.J.2
Marchesini, G.3
-
38
-
-
0035671770
-
Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients
-
Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients. Diabetologia 2001;44:2210.
-
(2001)
Diabetologia
, vol.44
, pp. 2210
-
-
Miyazaki, Y.1
Glass, L.2
Triplitt, C.3
-
39
-
-
0034833667
-
Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
-
Miyazaki Y, Mahankali A, MatsudaM, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710.
-
(2001)
Diabetes Care
, vol.24
, pp. 710
-
-
Miyazaki, Y.1
Mahankali, A.2
Matsuda, M.3
-
40
-
-
0034735992
-
Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone
-
Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278:704.
-
(2000)
Biochem Biophys Res Commun
, vol.278
, pp. 704
-
-
Sakamoto, J.1
Kimura, H.2
Moriyama, S.3
-
41
-
-
0036481709
-
Synthetic peroxisome proliferatoractivated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients
-
Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferatoractivated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25: 376-80.
-
(2002)
Diabetes Care
, vol.25
, pp. 376-380
-
-
Yang, W.S.1
Jeng, C.Y.2
Wu, T.J.3
|